Eurofins showcases clinical trial solutions at AAPS 2026 PharmSci 360
Eurofins will highlight integrated services and case studies designed to support clients across the entire drug development lifecycle
26 Oct 2026
By combining scientific expertise, regulatory experience, and fit-for-purpose analytical strategies, Eurofins Clinical Trial Solutions supports sponsors across complex drug development programs and emerging therapeutic modalities. Eurofins will be showcasing Clinical Trial Solutions at AAPS 2026 PharmSci 360 taking place October 25–28, in New Orleans, US.
The Eurofins team will be available to discuss:
- Bioanalytical assay development and validation
- Biomarker testing to support preclinical and clinical development
- Molecular and genomic bioanalysis, including qPCR and dPCR
- Immunogenicity and neutralizing antibody assays
- Flow cytometry and cell-based assays
- Pharmacokinetic (PK) and pharmacodynamic (PD) testing
- Central laboratory services
In addition, Mark Wissel, PhD, Director, R&D, will be presenting during AAPS 2026 PharmSci 360 as part of the symposium ‘Building Regulatory Confidence in Molecular Assays’. He will explore vector shedding bioanalysis and strategies to support gene therapy and other advanced therapeutic development programs. ‘Case Studies in Vector Shedding’ will be taking place on Monday, October 26, from 10:00–10:30 CT.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Links
Tags
Frequently asked questions
Show frequently asked questions
What clinical trial solutions will Eurofins showcase at AAPS 2026 PharmSci 360?
Eurofins will showcase bioanalytical assay development and validation, biomarker testing, molecular and genomic bioanalysis using qPCR and dPCR, immunogenicity and neutralizing antibody assays, flow cytometry, cell-based assays, PK/PD testing, and central laboratory services.
When and where is AAPS 2026 PharmSci 360 taking place?
AAPS 2026 PharmSci 360 will take place October 25–28, 2026, in New Orleans, US. Eurofins Clinical Trial Solutions will attend to discuss its scientific, regulatory, and fit-for-purpose analytical support for complex drug development programs and emerging therapeutic modalities.
What will Mark Wissel present at AAPS 2026 PharmSci 360?
Mark Wissel, PhD, Director, R&D, will present “Case Studies in Vector Shedding” on Monday, October 26, 2026, from 10:00–10:30 CT. He will discuss vector shedding bioanalysis and strategies supporting gene therapy and other advanced therapeutic development programs.